Regeneron reports strong early data for ubamatamab in ovarian cancer and trevogrumab in obesity trials
Regeneron Pharmaceuticals presented Phase 1/2 results for ubamatamab in recurrent low‑grade serous ovarian cancer and Phase 2 COURAGE trial data for trevogrumab in adults with obesity receiving semaglutide. The ubamatamab cohort showed a 73% objective response rate with a median progression‑free survival of 11 months, while trevogrumab preserved lean mass and thigh muscle volume compared with semaglutide alone. The company said it will advance ubamatamab into a confirmatory Phase 3 study and start a new Phase 2 trial of trevogrumab with GLP‑1 therapies, and it plans to consult the FDA on the ovarian cancer program.
Why it matters
Regeneron expects the positive data to support enrollment in larger registrational trials and to enable discussions with the FDA, which could affect future approval prospects and revenue potential. The muscle‑preserving results may broaden the market for trevogrumab in obesity management, potentially adding a new revenue stream.
Key facts
- 1Ubamatamab achieved a 73% objective response rate among 11 patients receiving 800 mg monotherapy in the Phase 1/2 LGSOC trial. rttnews.com
- 2The median progression‑free survival for ubamatamab in the same cohort was 11 months. benzinga.com
- 3The median duration of response for ubamatamab was nine months. rttnews.com
- 4In the COURAGE trial, trevogrumab preserved lean mass at Week 52 with a 5.8% decline versus a 7.3% decline for semaglutide alone (25 mg dose). rttnews.com
- 5Trevogrumab preserved 71.8% and 68.9% of thigh muscle volume at Week 52 for the 25 mg and 75 mg doses, respectively. rttnews.com
- 6Regeneron plans to initiate a Phase 2 trial of trevogrumab combined with GLP‑1 receptor agonists in older adults with obesity and reduced muscle mass. benzinga.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.